Oncology
Ensartinib Lowers Recurrence Risk in ALK-Positive NSCLC
A phase 3 trial found that daily ensartinib substantially prolonged disease-free survival after chemotherapy and complete resection of stage IB-IIIB ALK-positive NSCLC.
Dr. Abu Bakar · August 18, 2026 · 6 min